SOLICITATION NOTICE
66 -- Notice of Intent to Sole Source
- Notice Date
- 5/5/2017
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-1182669
- Archive Date
- 6/3/2017
- Point of Contact
- Christine L. Russman, Phone: 3017967841
- E-Mail Address
-
Christine.Russman@fda.hhs.gov
(Christine.Russman@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Document Type: Notice of Intent to Sole Source Solicitation Number: FDA - Sole Source - 1182669 Posted Date: 5 May 2017 Response Date: 19 May 2017 NAICS Code: 334516, Analytical Laboratory Instrument Manufacturing, Small Size Standard 1,000 Employees. The Food and Drug Administration intends to make a sole source award for Nextera XT DNA Sample Prep Kits and Nextera XT Index kits in the amount of $27,456.71. The award will be made to: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 In accordance with FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. FDA requires eight (8) Nextera XT DNA Sample Prep Kit (96 Samples) and four (4) Nextera XT Index Kit (96 indexes, 384 samples). NGS method- and C1 instrument-specific reagents are required for processing of cDNA from single cells using the Fluidigm C1 instrument. Experimental process-specific consumables are required for NGS sequencing after processing single cells with the Fluidigm C1 instrument. Illumina's unique Nextera reagents and kits are specified by Fluidigm for downstream processing of materials produced by the C1 instrument. Illumina collaborates with Fluidigm to provide unique reagents and consumables that Fluidigm specifies for downstream processing of materials made in the C1 processor. Illumina is the only supplier of these instrument- and process-specific reagents. This notice of intent is not a request for competitive quotes. However, all responsible sources may submit a capability statement within five (5) days after the publication of this synopsis which shall be considered by the agency. Responses received after 5 days or without the required information may not be considered. For information concerning this acquisition contact: Christine Russman Contract Specialist Christine.Russman@fda.hhs.gov (301) 796 - 7841. A determination by the Government not to compete as a result of information received is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-1182669/listing.html)
- Place of Performance
- Address: The US Food and Drug Administration, White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN04498365-W 20170507/170505234945-842889f1715a589552d977bdd0eac3a2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |